TVGN Tevogen Bio Holdings Inc.
8-K Current Report
Filed: February 25, 2026
Health Care
Biological Products, (No Diagnostic Substances)Tevogen Bio Holdings Inc. (TVGN) 8-K current report filed with SEC EDGAR on February 25, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items2 items
- Item 5.02: Departure/Election of Directors or Officers
- Item 5.07: Submission of Matters to a Vote of Security Holders
AI Filing Analysis8-K
Item 5.02 · Departure/Election of Directors or Officers
- • Special Meeting held Feb 19, 2026 — filing appears truncated, full officer change details not captured in provided text
- • Item 5.02 signals a material leadership change (departure, appointment, or compensation update) — full exhibit review required for specifics
Item 5.07 · Submission of Matters to a Vote of Security Holders
- • Reverse split ratio approved: 1:25 to 1:85, exact ratio and timing at Board's sole discretion — significant dilution risk reduction but share count compression pending
- • Reverse split passed with 176.3M votes for vs. 6.0M against (~96.7% approval) out of 182.4M shares present
Other Tevogen Bio Holdings Inc. 8-K Filings
Get deeper insights on Tevogen Bio Holdings Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.